AzTrials
AzTrials

AnovulationCOLANCT02309047

The Cycle Disturbances, OLigomenorrhea and Amenorrhea (COLA) Study & Biobank

An observational study of Anovulation, run by UMC Utrecht at 1 site in Netherlands.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Through the COLA Study and Biobank the investigators hope to enable further identification of phenotype, endocrine, ethnic, and metabolic characteristics associated with menstrual cycle disturbances; and: the identification of genetic or other etiologic factors associated with cycle disturbances. Read more about this study

Who is it for?
Ages 18 to 45 years, women only
Conditions the study is for
Anovulation
How many people
5,000 participants
Where
1 siteNetherlands
Study dates
Oct 2004to Aug 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 45 years
  • Women only
  • No healthy volunteers
  • Adult

Study population: Women with cycle disturbances are referred to the outpatient clinic specialized in cycle disturbances by 1st or 2nd line care providers for further diagnostic procedures.

Who may be able to join

  • WHO I Hypogonadotropic hypoestrogenic status (previously: "hypothalamic amenorrhea")
  • Low to normal serum FSH concentrations
  • Low serum estradiol concentrations
  • WHO II
  • Amenorrhea or oligomenorrhea (mean cycle >35 days during the last 6 months)
  • Normal serum FSH concentrations (<12 IU/L)
Show all 18Show fewer
  • Absence of other causes for the cycle disturbance, including: normal prolactin concentrations (<1.0 IU/L), normal TSH concentrations (0.2 - 4.2 milliunits/L), abnormalities on ultrasonography.
  • Within women with WHO II status, PCOS is diagnosed when at least 2 of the following criteria are met:
  • Oligo-/anovulation
  • Clinical and/ or biochemical hyperandrogenism
  • Polycystic ovaries on ultrasonography
  • WHO III
  • POI: defined as secondary amenorrhea before the age of 40 years and basal FSH > 40 IU/L.
  • IOF: defined as normal ovulatory cycles with raised basal FSH > 12 IU/L before the age of 40 years.
  • TOF: defined as irregular cycles with raised basal FSH > 12 IU/L before the age of 40 years.
  • Poor ovarian response: defined as less than 4 oocytes retrieved or cancellation in case of absent follicle growth after ovarian hyperstimulation with 300 IU gonadotropins.
  • Early menopause: menopause occurring between age 40 and 45 years.
  • Hypergonadotropic primary amenorrhea: primary amenorrhea with raised basal FSH > 12 IU/L.

Who cannot join

  • Age: younger than 18 yrs.
  • Regularly cycling women, with the exception of women with elevated basal FSH concentrations (IOF cases).

Trial locations and contacts

1 site in 1 country.

Netherlands1 site, 1 recruiting
  • University Medical Center Utrecht

    Utrecht, 3508GA

    Bart CJ Fauser, professor, +31887557524, b.c.fauser@umcutrecht.nl

    Nadine MP Daan, MD, +31877551044, n.m.p.daan@umcutrecht.nl

    Recruiting

Other trials in Netherlands

About this study

Through the COLA Study and Biobank the investigators hope to enable further identification of phenotype, endocrine, ethnic, and metabolic characteristics associated with menstrual cycle disturbances; and: the identification of genetic or other etiologic factors associated with cycle disturbances.

Read the detailed description

Population Women with cycle disturbances are referred to the outpatient clinic specialized in cycle disturbances by 1st or 2nd line care providers for further diagnostic procedures.

Inclusion criteria WHO I Hypogonadotropic hypoestrogenic status (previously: "hypothalamic amenorrhea")

  1. Low to normal serum follicle-stimulating hormone (FSH) concentrations
  2. Low serum estradiol concentrations

WHO II

  1. Amenorrhea or oligomenorrhea (mean cycle >35 days during the last 6 months)
  2. Normal serum FSH concentrations (<12 IU/L)
  3. Absence of other causes for the cycle disturbance, including: normal prolactin concentrations (<1.0 IU/L), normal thyroid stimulating hormone (TSH) concentrations (0.2 - 4.2 milli-International unit /L), abnormalities on ultrasonography.

Within women with WHO II status, polycystic ovary syndrome (PCOS) is diagnosed when at least 2 of the following criteria are met:

  1. Oligo-/anovulation
  2. Clinical and/ or biochemical hyperandrogenism
  3. Polycystic ovaries on ultrasonography

WHO III

  1. primary ovarian insufficiency (POI): defined as secondary amenorrhea before the age of 40 years and basal FSH > 40 IU/L.
  2. incipient ovarian failure (IOF): defined as normal-ovulatory cycles with raised basal FSH > 12 IU/L before the age of 40 years.
  3. transient ovarian failure (TOF): defined as irregular cycles with raised basal FSH > 12 IU/L before the age of 40 years.
  4. Poor ovarian response: defined as less than 4 oocytes retrieved or cancellation in case of absent follicle growth after ovarian hyperstimulation with 300 IU gonadotropins.
  5. Early menopause: menopause occurring between age 40 and 45 years.
  6. Hypergonadotropic primary amenorrhea: primary amenorrhea with raised basal FSH > 12 IU/L. Controls For analyses in which comparison with female controls are needed, data will be collected from existing population based cohorts, such as the EPIC cohort (Julius Center), or selected women included in the preconceptional cohort (PC, derived from the Department of Reproductive Medicine and Gynaecology in the University Medical Center Utrecht (UMCU), separate protocol in preparation).

Exclusion criteria

  • Age: younger than 18 yrs.
  • Regularly cycling women, with the exception of women with elevated basal FSH concentrations (IOF cases).

Study parameters In order to determine the phenotype characteristics of women with cycle disturbances, and to allow for the identification of genetic factors associated with cycle disturbances, the following parameters will be obtained.

  • Age
  • Ethnicity
  • Social economic status and education
  • Intoxications: smoking habits (previous and current), use of alcohol or drugs
  • Medication and medication history
  • Mental health (depression, stress and anxiety)
  • Cycle regularity: age at menarche, use of (oral/intrauterine) contraceptives, mean duration of cycle, variation in cycle duration.
  • Reproductive \& obstetric history: parity, time to pregnancy and pregnancy outcome, subfertility (including treatments)
  • Medical history (including previous gonadotoxic treatment)
  • Family history of diabetes mellitus, early menopause, cycle irregularities, subfertility, cardiovascular disease, endocrinological disease, congenital disorders
  • Basic physical examination: systolic and diastolic blood pressure, height, weight (BMI), waist circumference, hip circumference
  • Assessment of hirsutism, acne, Tanner sexual development stages.
  • Ovarian reserve parameters: antral follicle count, ovarian volume, anti-müllerian hormone (AMH)
  • luteinizing hormone (LH), FSH, prolactin, TSH, estradiol concentrations
  • Androgen levels
  • Lipid spectrum, glucose, insulin, High sensitivity C-reactive protein
  • In POI specifically: bone density as assessed by dual-energy X-ray absorptiometry (DEXA), karyotype, fragile X premutation screening, presence of autoantibodies (against thyroid, ovaries, parietal cells and adrenal gland).

Participation in the COLA Biobank will consist of the additional withdrawal of two blood vials (one for DNA and one for serum sampling) obtained during the routine diagnostic procedure.

Relatives of the index patient:

When a familial tendency of the WHO status is suspected on the basis of family history of 1st and 2nd degree relatives, these relatives will be invited for participation of the study.

Conditions
Anovulation
Medical subject headings
Anovulation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT02309047
Study groupRoleWhat they receive
WHO anovulationWHO I, II. III anovulation. See inclusion criteria

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. hormonal classification

    FSH, LH, Estradiol, Progesterone,Testosterone, Androstenedione, Sex hormone binding globulin (SHBG), Cortisol, TSH

    Measured: within 6 weeks

  2. metabolic profile

    total cholesterol, triglycerides, LDL cholesterol, HDL cholesterol, insulin, glucose

    Measured: within 6 weeks

  3. ovarian reserve

    anti mullerian hormone, FSH and antral follicle count.

    Measured: within 6 weeks

Secondary outcomes (3)
  1. autoimmunity in WHO 3- POI patients

    antithyroid peroxidase, antiadrenal, antiparietal and antiovarian antibodies

    Measured: within 3 months

  2. bone density in WHO 3- POI patients

    a dual-energy x-ray absorptiometry (DEXA) scan

    Measured: within 3 months

  3. genotype in WHO 3 POI patients

    karotype, fragile X mental retardation 1 gene premutation carriership

    Measured: within 3 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Dec 2014 (estimated)
  2. Study startOct 2004
  3. Primary completionJun 2022 (estimated)
  4. Study completionAug 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
5,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02309047
Sponsor's protocol ID
12-645
Acronym
COLA
Status last verified
Oct 2021
First submitted
12 Nov 2014
Last updated
20 Oct 2021
Results posted
No
Data monitoring committee
No

Publications

  • Christ JP, Gunning MN, Meun C, Eijkemans MJC, van Rijn BB, Bonsel GJ, Laven JSE, Fauser BCJM. Pre-Conception Characteristics Predict Obstetrical and Neonatal Outcomes in Women With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2019 Mar 1;104(3):809-818. doi: 10.1210/jc.2018-01787.

    PubMed 30590587
  • Christ JP, Gunning MN, Palla G, Eijkemans MJC, Lambalk CB, Laven JSE, Fauser BCJM. Estrogen deprivation and cardiovascular disease risk in primary ovarian insufficiency. Fertil Steril. 2018 Apr;109(4):594-600.e1. doi: 10.1016/j.fertnstert.2017.11.035. Epub 2018 Mar 28.

    PubMed 29605405

Questions about this trial

What is this clinical trial studying?

An observational study of Anovulation, run by UMC Utrecht at 1 site in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 18 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 20 Oct 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

hormonal classification (time frame: within 6 weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02309047, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in